24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
LAPALIEVA 250 MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | LAPALIEVA 250 MG |
|---|---|
| Composition | Lapatinib Tablets 250 mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (30 tab) |
| Country of Origin | India |
Lapatinib Tablets 250 mg (Lapatinib Tablets 250 mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
LAPALIEVA 250 MG (Lapatinib Tablets 250 mg) is a targeted anticancer medicine used in the treatment of certain types of HER2-positive breast cancer. It contains Lapatinib, an advanced tyrosine kinase inhibitor (TKI) that works by blocking specific proteins responsible for the growth and spread of cancer cells. This targeted therapy is widely prescribed by oncologists for patients with advanced, metastatic, or treatment-resistant breast cancer.
Breast cancer remains one of the most commonly diagnosed cancers worldwide. In some patients, cancer cells produce excessive amounts of a protein known as Human Epidermal Growth Factor Receptor 2 (HER2). This protein promotes rapid cancer cell growth and increases the aggressiveness of the disease. LAPALIEVA 250 MG helps control this process by targeting HER2 and Epidermal Growth Factor Receptor (EGFR), thereby slowing cancer progression and supporting long-term disease management.
Unlike traditional chemotherapy, Lapatinib specifically targets cancer-related pathways, making it an important component of modern precision oncology treatment. It is often used in combination with other anticancer medicines to improve treatment outcomes and help patients achieve better disease control.
LAPALIEVA 250 MG is commonly prescribed for:
• HER2-positive metastatic breast cancer
• Advanced breast cancer
• Hormone receptor-positive and HER2-positive breast cancer
• Recurrent breast cancer
• Combination targeted therapy protocols
• Long-term oncology treatment programs
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, efficacy, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and cancer treatment.
Patients receiving LAPALIEVA 250 MG may require regular medical monitoring, imaging studies, liver function assessments, and cardiac evaluations throughout therapy. These assessments help doctors evaluate treatment effectiveness and identify any potential complications early.
Because of its proven effectiveness in HER2-positive breast cancer treatment, LAPALIEVA 250 MG has become an important part of modern targeted cancer therapy and personalized oncology care.
LAPALIEVA 250 MG (Lapatinib Tablets 250 mg) is mainly used for the treatment and management of HER2-positive breast cancer and related oncology conditions.
The medicine is widely used in patients diagnosed with HER2-positive breast cancer, where cancer cells overexpress HER2 proteins.
Doctors may prescribe LAPALIEVA for patients with advanced-stage breast cancer requiring targeted treatment.
Lapatinib helps manage breast cancer that has spread to other parts of the body.
The medicine may be used in patients whose cancer has returned after previous treatment.
LAPALIEVA is often prescribed along with other anticancer medicines as part of combination treatment protocols.
Targeted therapy helps support ongoing disease management and may slow cancer progression in eligible patients.
Lapatinib belongs to a group of medicines known as Tyrosine Kinase Inhibitors (TKIs).
LAPALIEVA works by:
• Blocking HER2 receptors
• Inhibiting EGFR signaling pathways
• Preventing cancer cell multiplication
• Slowing tumor growth
• Reducing cancer progression
• Supporting targeted oncology treatment
This dual-target mechanism helps control HER2-positive breast cancer more effectively and improves treatment outcomes in suitable patients.
Like other targeted cancer medicines, LAPALIEVA 250 MG may cause side effects in some patients. Side effects vary depending on individual health conditions and treatment response.
Digestive disturbances and loose stools are among the most frequently reported side effects.
Some patients may experience nausea or stomach discomfort during treatment.
Tiredness, weakness, or reduced energy levels may occur.
Skin irritation, redness, or acne-like rash may develop during therapy.
Patients may experience reduced appetite or changes in eating habits.
Oral ulcers or mouth discomfort may occasionally occur.
Some patients may develop redness, pain, or sensitivity in the hands and feet.
Mild to moderate vomiting may occur in certain individuals.
Skin dryness or itching may be observed during treatment.
Although uncommon, certain serious side effects require immediate medical attention.
• Severe diarrhea
• Difficulty breathing
• Chest pain
• Irregular heartbeat
• Severe allergic reactions
• Yellowing of the skin or eyes
• Severe skin reactions
• Signs of liver problems
• Significant swelling or fluid retention
Patients should contact their healthcare provider immediately if any serious symptoms occur.
The dosage of LAPALIEVA 250 MG (Lapatinib Tablets 250 mg) should always be determined by a qualified oncologist based on the patient's condition and treatment plan.
The specific cancer diagnosis and HER2 status influence treatment decisions.
Dosage may vary depending on whether Lapatinib is used alone or with other anticancer medicines.
Patients with liver impairment may require dosage adjustments.
Age, body weight, and general health status affect treatment planning.
Doctors may modify dosage based on treatment effectiveness and side effect management.
• Take the medicine exactly as prescribed.
• Swallow tablets whole with water.
• Do not crush, chew, or break the tablets.
• Take the medication at the same time every day.
• Follow the prescribed treatment schedule carefully.
• Do not stop treatment without consulting your doctor.
Regular medical monitoring is important throughout therapy.
Before starting treatment, patients should inform their doctor if they have:
• Liver disease
• Heart disease
• Kidney disorders
• Previous cancer treatment complications
• Digestive disorders
• History of severe allergic reactions
Patients should also discuss all prescription medicines, supplements, and herbal products currently being used to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
• Store in a cool and dry place.
• Protect from direct sunlight and moisture.
• Keep out of reach of children.
• Store at recommended room temperature.
• Advanced targeted breast cancer therapy
• Effective HER2 and EGFR inhibitor formulation
• Trusted oncology treatment support
• Suitable for HER2-positive breast cancer management
• Manufactured under strict pharmaceutical quality standards
• Reliable long-term disease control option
• Supports modern personalized cancer treatment strategies
It is mainly used for the treatment of HER2-positive advanced or metastatic breast cancer.
Lapatinib is a targeted anticancer medicine that blocks HER2 and EGFR receptors to help slow cancer growth.
No, it is a targeted therapy medicine and works differently from traditional chemotherapy.
Yes, doctors often prescribe it in combination with other anticancer therapies for improved treatment outcomes.
HER2-positive breast cancer is a type of breast cancer in which cancer cells produce excess HER2 protein, leading to faster growth.
Yes, diarrhea is one of the most commonly reported side effects and should be monitored carefully.
Yes, doctors usually recommend liver function tests, cardiac monitoring, and routine medical assessments during therapy.
Yes, this medicine should always be used under the supervision of qualified healthcare professionals experienced in oncology treatment.